Cabaletta Bio is excited to be attending today's #LupusABC Meeting on Patient Reported Outcomes in clinical trials! We’re joining leading experts and the #lupus community to chart the best course for integrating patient priorities and needs into the drug evaluation process. More about Lupus ABC: lupusabc.org #LupusVoices #LupusResearch
Cabaletta Bio’s Post
More Relevant Posts
-
Excited to be at the #LupusABC Meeting on Patient Reported Outcomes in clinical trials! We’re joining leading experts and the #lupus community to chart the best course for integrating patient priorities and needs into the drug evaluation process. Learn more: lupusabc.org #LupusResearch #LupusVoices
-
-
Patient Advocate | Lived Experience Expert | Keynote Speaker | Innovator | Thought Leader | Patient Engagement Leader | Founding Member & Cohort Leader at Chronic Boss Collective
Last week I was in Las Vegas, this week, San Francisco! I'm honored to be speaking at Clinical Trials in Rare Diseases on Engaging patients beyond just participating in a trial: the role of biopharma companies in supporting patients. #PatientCentricity means truly putting the patients at the forefront of your research and development. Supporting patients throughout the entire lifecycle of rare disease research and clinical trials and beyond as well as giving them a voice in the process is the only way to maximize your ROI! #clinicaltrials #patientadvocacy #patientengagement #patientsupport #research #treatment #patientvoice #biotech #pharma #healthtech #realworldevidence #realworlddata #researchanddevelopment #patientexperience #patientsolutions #orphandrugs #raredisease
-
-
With a staggering 7,000 rare diseases spanning various therapeutic areas, take a moment to discover the latest collaborations, frameworks, and portfolios designed to support drug development. Explore the extraordinary: https://okt.to/VXlq1J #cellandgenetherapies #CGT #advancedtherapies #raredisease
-
-
Driving impactful narratives and strategic growth through innovative communication and marketing leadership.
With a staggering 7,000 rare diseases spanning various therapeutic areas, take a moment to discover the latest collaborations, frameworks, and portfolios designed to support drug development. Explore the extraordinary: https://okt.to/8OuBjZ #cellandgenetherapies #CGT #advancedtherapies #raredisease
-
-
With a staggering 7,000 rare diseases spanning various therapeutic areas, take a moment to discover the latest collaborations, frameworks, and portfolios designed to support drug development. Explore the extraordinary: https://okt.to/jU3zZs #cellandgenetherapies #CGT #advancedtherapies #raredisease
-
-
Business Development Manager, Gene Therapy CDMO Services - East @ Charles River Labs
With a staggering 7,000 rare diseases spanning various therapeutic areas, take a moment to discover the latest collaborations, frameworks, and portfolios designed to support drug development. Explore the extraordinary: https://okt.to/1e6Cl2 #cellandgenetherapies #CGT #advancedtherapies #raredisease #genetherapy
-
-
Business Development Manager Central/South Spain Charles River Laboratories
With a staggering 7,000 rare diseases spanning various therapeutic areas, take a moment to discover the latest collaborations, frameworks, and portfolios designed to support drug development. Explore the extraordinary: https://okt.to/0akMqB #cellandgenetherapies #CGT #advancedtherapies #raredisease
-
-
With a staggering 7,000 rare diseases spanning various therapeutic areas, take a moment to discover the latest collaborations, frameworks, and portfolios designed to support drug development. Explore the extraordinary: https://okt.to/otKifp #cellandgenetherapies #CGT #advancedtherapies #raredisease
-
-
With a staggering 7,000 rare diseases spanning various therapeutic areas, take a moment to discover the latest collaborations, frameworks, and portfolios designed to support drug development. Explore the extraordinary: https://okt.to/wuSb1U #cellandgenetherapies #CGT #advancedtherapies #raredisease
-
-
2025 promises to represent another rich year of progress. https://ow.ly/5JxC50TKMAf A wealth of new therapies are set to successfully graduate from the pipeline. Within this cohort are a mixture of therapeutic areas, drug classes, first-time approvals, label expansions, and, most importantly, treatments that will meaningfully change how diseases are treated. This article provides a snapshot of these advancements and the potential new approvals to add to your vocabulary, from apitegromab to Zegalogue. Click the link in this post to read the article.
